Business Context and Reporting Period
Company: Aptevo Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2016
Event: Entry into a Material Definitive Agreement and Creation of a Direct Financial Obligation.
Key Financial Metrics and Debt Structure
This filing details a new credit facility rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Total Credit Facility: $35 million.
- Tranche 1: $20 million available immediately upon closing (August 4, 2016).
- Tranche 2: $15 million available subject to conditions (see below).
- Interest Rate: LIBOR plus 7.60% per annum.
- Amortization: Monthly commencing August 2018.
- Maturity Date: February 1, 2021.
- Collateral: Secured by all assets except certain voting shares of excluded subsidiaries, specific contracts, and intellectual property (except to the extent necessary to secure proceeds).
- Fees: Includes an agency fee, an exit fee of up to 5.75% on early repayment/prepayment, and a prepayment fee of up to 4% in the first year (decreasing over time).
Material Changes and Conditions
The primary material change is the establishment of the $35 million Credit and Security Agreement with MidCap Financial Trust as agent. The availability of the second tranche ($15 million) is contingent upon Aptevo meeting two specific conditions:
- Achieving net commercial product revenue of $40 million on a trailing twelve-month basis.
- Receiving an additional $20 million in cash from Emergent BioSolutions Inc. (evidenced by a promissory note).
The agreement imposes financial covenants requiring increasing minimum net commercial product revenue for each twelve-month period ending on the last day of each calendar quarter, starting September 30, 2016.
Outlook, Risks, and Contingencies
Management Commentary and Forward-Looking Statements: The filing includes a Safe Harbor statement noting that forward-looking statements regarding future revenue and the closing of the second tranche are based on current expectations and are not guaranteed.
Risks and Contingencies:
- Covenants: Negative covenants restrict indebtedness, liens, dividends, mergers, acquisitions, and transactions with affiliates.
- Events of Default: Include failure to pay principal/interest, covenant defaults, cross-defaults on other material indebtedness, breach of material contracts, or commencement of liquidation/reorganization.
- Operational Risks: Potential negative effects from the separation from Emergent BioSolutions, deterioration in business prospects, adverse market developments, and regulatory changes.
Investor Verification Checklist
- Verify the current status of the $20 million promissory note from Emergent BioSolutions Inc. required to unlock the second tranche.
- Monitor Aptevo's trailing twelve-month net commercial product revenue to ensure compliance with the $40 million threshold for the second tranche and ongoing financial covenants.
- Review the full text of the Credit Agreement (Exhibit 10.1) and Fee Letter (Exhibit 10.2) for specific definitions of "net commercial product revenue" and detailed covenant restrictions.
- Assess the impact of the high interest rate (LIBOR + 7.60%) and prepayment fees on future cash flow projections.